PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.00 - 0.01
0.00 - 0.02
289 / 496.9K (Avg.)
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-19.26%
Negative revenue growth while ECL.AX stands at 22.66%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-20.12%
Negative gross profit growth while ECL.AX is at 21.84%. Joel Greenblatt would examine cost competitiveness or demand decline.
-99.81%
Negative EBIT growth while ECL.AX is at 33.26%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-99.81%
Negative operating income growth while ECL.AX is at 33.26%. Joel Greenblatt would press for urgent turnaround measures.
-136.77%
Negative net income growth while ECL.AX stands at 3066.59%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-100.00%
Negative EPS growth while ECL.AX is at 3090.91%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-100.00%
Negative diluted EPS growth while ECL.AX is at 3090.91%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
8.80%
Share change of 8.80% while ECL.AX is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
8.80%
Diluted share change of 8.80% while ECL.AX is zero. Bruce Berkowitz might see a minor difference that could widen over time.
No Data
No Data available this quarter, please select a different quarter.
-110.07%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-370.56%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
-43.03%
Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.
-24.94%
Negative 3Y CAGR while ECL.AX stands at 4.23%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
No Data
No Data available this quarter, please select a different quarter.
95.28%
Positive OCF/share growth while ECL.AX is negative. John Neff might see a comparative advantage in operational cash viability.
96.04%
Positive 3Y OCF/share CAGR while ECL.AX is negative. John Neff might see a big short-term edge in operational efficiency.
96.53%
Net income/share CAGR at 75-90% of ECL.AX's 128.23%. Bill Ackman would press for strategic moves to boost long-term earnings.
20.63%
5Y net income/share CAGR at 75-90% of ECL.AX's 27.12%. Bill Ackman would advocate improvements to match competitor’s profit expansion.
50.80%
Below 50% of ECL.AX's 158.17%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
137.94%
R&D growth of 137.94% while ECL.AX is zero. Bruce Berkowitz checks if the moderate investment leads to meaningful product differentiation.
-40.51%
We cut SG&A while ECL.AX invests at 12.79%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.